EMA Authorised: Nintedanib Accord (nintedanib) — Accord Healthcare S.L.U.

View source ↗

Summary

EU authorization of Nintedanib Accord for idiopathic pulmonary fibrosis and related interstitial lung diseases, expanding treatment options in the EU.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis
• Interstitial Lung Disease
• Pulmonary Fibrosis
• Scleroderma Systemic

Drugs mentioned

• Nintedanib Accord (nintedanib)

Snippet

Status: Authorised. Therapeutic area: Idiopathic Pulmonary Fibrosis;Lung Diseases, Interstitial;Scleroderma, Systemic;Pulmonary Fibrosis. MAH: Accord Healthcare S.L.U.. Decision date: 22/06/2026